AsianScientist (Feb. 9, 2012) – Takeda Pharmaceutical Company Limited announced today the establishment of the Takeda Shanghai Development Center (TSDC) within its wholly owned subsidiary, Takeda (China) Holdings Co. Ltd.
Reflecting a strategic commitment to Asia and to China in particular, Takeda Pharmaceutical (China) Company Limited in Taizhou (Takeda China) will be responsible for marketing and sales, and Tianjin Takeda Pharmaceuticals Co., Ltd, in Tianjin (Takeda Tianjin) will be responsible for manufacturing.
Within Asia outside Japan, including China, drug development is overseen by Takeda Global Research & Development Center (Asia) Pte. Ltd. in Singapore and Millennium Pharmaceuticals Inc. in Cambridge, both wholly owned subsidiaries of Takeda, through outsourcing to contract research organizations.
Together with Takeda China and Tianjin Takeda, TSDC will work on extending and enhancing the company’s clinical development activities within the Asian region, with a focus on China for general medicine and across Asia for oncology.
Through TSDC, Takeda will continue to conduct clinical trials towards regulatory approval in Asia, with a growing emphasis on China, and continue to build deeper relationships with physicians and regulatory authorities.
——
Source: Takeda Pharmaceutical Co.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
